NCT00521859View on ClinicalTrials.gov

Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Hematologic Malignancies

Interventions

DRUG

Cloretazine

800 mg/m\^2 by vein daily

DRUG

Fludarabine

25 mg/m\^2 by vein daily x 5 Days

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Vion Pharmaceuticals

All Listed Sponsors

collaborator

Vion Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00521859 - Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies | Biotech Hunter | Biotech Hunter